latest news releases from the newsroom
Leisure Direct Inc.
Leisure Direct to Consolidate $60 Billion Pool, Spa, and Backyard Recreation Industry -- As Reported by Wallstreetcorner.com
PERRYSBURG, Ohio, Dec. 14, 2004 (PRIMEZONE) -- Leisure Direct, Inc. (OTCBB:LDTI) is pleased to announce that they have been featured on Wallstreetcorner.com. In his interview with Larry Oakley, Leisure Direct, Inc. CEO, John R. Ayling stated, "We expect to consolidate a portion of the $60 billion pool, spa, and backyard recreation industry and become the premier, highest quality, and most nationally recognized manufacturer and direct marketer of pool, spa, and patio products in the United States."
The Pomerantz Firm Charges IMPAX Laboratories, Inc. With Securities Fraud -- IPXL
NEW YORK, Dec. 14, 2004 (PRIMEZONE) -- Pomerantz Haudek Block Grossman & Gross LLP (www.pomerantzlaw.com) has filed a class action lawsuit against IMPAX Laboratories, Inc. ("IMPAX" or the "Company") (Nasdaq:IPXL) and individual defendants Barry D. Edwards (IMPAX CEO and a Director) and Cornel C. Spiegler (IMPAX CFO), on behalf of all persons or entities who purchased the securities of IMPAX during the period from May 5, 2004 to November 3, 2004, inclusive (the "Class Period"). The case, Civil Action Number 04 5252 in the United States District Court, Northern District of California, is assigned to Judge Charles R. Bryer.
Emtec Inc. Announces Increased Credit Facility At Reduced Cost
TRENTON, N.J., Dec. 14, 2004 (PRIMEZONE) -- Emtec Inc. (OTCBB:ETEC), a systems integrator providing technology solutions to enable customers to effectively use and manage data to grow their businesses, today announced that it has entered into an amendment on December 10, 2004, to Loan and Security Agreement with Bank of America Business Capital Corporation (successor by merger to Fleet Capital Corporation) ("BOA"), extending its credit facility through November 21, 2006. This amendment increases Emtec's credit facility from $10 million to $12 million. Emtec can borrow up to a lesser of $12 million minus the outstanding letter of credit obligations or 85 percent of eligible accounts receivable minus the outstanding letter of credit obligations. This amendment reduced Emtec's interest rate from 1.00 percent above the prime rate to 0.25 percent above the prime rate. All other material terms of this agreement remain unchanged.
Nicodrops Receives Order from The Largest U.S. Drug Chain
LA MESA, Calif., Dec. 14, 2004 (PRIMEZONE) -- Nicodrops, Inc. (Pink Sheets:NCDP), developer of the world's first drug-free, non-nicotine smoking cessation lozenge, today announced an agreement with CVS Pharmacies (NYSE:CVS) which will place their product in over 4,000 CVS stores coast to coast. Nicodrops has commenced shipping product to CVS Pharmacy warehouse distribution centers throughout the U.S.
Gardant Pharmaceuticals, Inc.
Bioaccelerate to Co-Develop Anti-Cancer Portfolio of Five Clinical and Three Pre-Clinical Products with Faustus Forschung Cie., Translational Cancer Research GmbH and Faustus Forschung Translational Drug Development AG, Vienna, Austria
NEW YORK, Dec. 14, 2004 (PRIMEZONE) -- Bioaccelerate Holdings Inc. New York (OTCBB:BACL) and Faustus Forschungs Cie. Translational Cancer Research GmbH and Faustus Forschung Translational Drug Development AG, Vienna, Austria, have entered into an agreement regarding the co-development of eight new anti-cancer drug candidates, five of which are in the Clinical development Stage and three in the pre-clinical development stage.